Uncategorized

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

Published

7 days ago

on

By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Vertex and others with similar assets.​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version